| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1592/PHCO.29.7.812 |
| P698 | PubMed publication ID | 19558255 |
| P2093 | author name string | Sarah A Spinler | |
| P2860 | cites work | Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 |
| Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke | Q24646522 | ||
| Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study | Q28165115 | ||
| Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis | Q28174135 | ||
| The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study | Q28174916 | ||
| Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials | Q28174968 | ||
| Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial | Q28181168 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study | Q28190808 | ||
| Adherence to medications by patients after acute coronary syndromes | Q28192360 | ||
| Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial | Q28193186 | ||
| Long-term adherence with cardiovascular drug regimens | Q28194045 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin | Q28195019 | ||
| Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events | Q28195656 | ||
| Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial | Q28199563 | ||
| Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials | Q28200013 | ||
| A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease | Q28200844 | ||
| Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial | Q28209556 | ||
| Aspirin dose for the prevention of cardiovascular disease: a systematic review | Q28210030 | ||
| Clinical aspects of platelet inhibitors and thrombus formation | Q28210313 | ||
| Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial | Q28210537 | ||
| Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial | Q28211092 | ||
| In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution | Q28211593 | ||
| Assessment of bleeding events in clinical trials--proposal of a new classification | Q28217723 | ||
| Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial | Q28218263 | ||
| Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation | Q28218789 | ||
| Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction | Q28218805 | ||
| Dose titration to reduce dipyridamole-related headache | Q28219340 | ||
| Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials | Q28219404 | ||
| Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants | Q28219972 | ||
| Rapid development of tolerance to dipyridamole-associated headaches | Q28343787 | ||
| The interaction of patient perception of overmedication with drug compliance and side effects | Q29306987 | ||
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Thrombotic thrombocytopenic purpura associated with clopidogrel | Q33332822 | ||
| Clopidogrel desensitization: case report and review of published protocols | Q33378440 | ||
| Peripheral nociception associated with surgical incision elicits remote nonischemic cardioprotection via neurogenic activation of protein kinase C signaling | Q33752527 | ||
| Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack | Q34344580 | ||
| Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788509 | ||
| Initial phase of chronic medication use; patients' reasons for discontinuation | Q35827473 | ||
| Cangrelor for treatment of coronary thrombosis | Q36440860 | ||
| Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs | Q36856026 | ||
| Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study | Q36938476 | ||
| 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in coll | Q37028681 | ||
| 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evide | Q37031817 | ||
| Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis | Q37054527 | ||
| A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes | Q40349752 | ||
| A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans | Q41868121 | ||
| European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke | Q42551725 | ||
| Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy | Q42640020 | ||
| Gastrointestinal bleeding after acute ischemic stroke | Q44068685 | ||
| Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r | Q44589935 | ||
| Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. | Q44923873 | ||
| Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. | Q45173221 | ||
| Clopidogrel and the concept of high-risk pharmacokinetics. | Q46034382 | ||
| Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. | Q46209759 | ||
| Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation | Q46711899 | ||
| Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries | Q46739685 | ||
| Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc | Q46868498 | ||
| Intensifying platelet inhibition--navigating between Scylla and Charybdis | Q46915041 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE | Q46916592 | ||
| Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). | Q47438826 | ||
| Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. | Q51182242 | ||
| Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. | Q51758758 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 812-821 | |
| P577 | publication date | 2009-07-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease | |
| P478 | volume | 29 |
| Q37961955 | A methodological framework for estimating the clinical and economic value of community pharmacists' clinical interventions using expert opinion |
| Q38817051 | Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials |
| Q43184658 | An aspirin a day: are we barking up the wrong willow tree? |
| Q37190867 | Potentially inappropriate prescribing in institutionalised older patients in Spain: the STOPP-START criteria compared with the Beers criteria. |
| Q88100157 | Resolution of clopidogrel-associated polyarthritis after conversion to prasugrel |
Search more.